UDK: 615.1:54
B. E. Tolkachev, O. V. Magnitskaya, L. A. Smirnova
Волгоградский государственный медицинский университет, кафедра фундаментальной медицины и биологии; кафедра клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ; 3 лаборатория клинической фарм
Evaluation of newly developed phenotyping probe in clinical practice was performed. Based on the results obtained, conclusion can be made, that ivabradine could be exploited as promising marker substrate in patients with compromised activity of CYP3A4 isoenzyme. It is also worth noting that metabolic «N-demethylivabradine/ivabradine» ratio could serve as a biomarker for pharmacotherapy optimization.
personalized medicine, ivabradine, phenotyping, CYP3A4, drug-metabolizing enzymes, chromatography